Celsius Holdings (CELH) Q3 sales jump 17%, but core brand weakness and falling margins challenge growth
Read More Pharma Industry News How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more. bySoujanya RaviApril 16, 2026